pharmaphorum4d
Gilead swoops to buy Kite for $12billion
That turned out to be one of the best pharma M&A deals of all time. But Gilead's hep C franchise peaked some time ago, and the firm needed another blockbuster to boost its prospects. Kite's lead ...
The Pharma Letter4h
Driving innovation in blood cancer: Gilead and Kite Oncology’s vision for the Middle East
Marking World Cancer Day 2025, this week's Executive Q&A is with Diego Santoro, General Manager & Head of International ...
BioSpace17d
Almost 5 Years into $5B Galapagos Partnership, Gilead Execs Start Over With New Spinoff
Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...
FiercePharma23d
Gilead's Kite taps longtime Amgen alum as new global commercial head
Kite Pharma is flying high with the addition of a new member to its senior leadership team. Brian Heath has joined Gilead Sciences’ cell therapy subsidiary as a senior vice president and head of ...
The Pharma Letter4h
BRIEF—Kite shares new data on CAR T cell therapy
Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the ...
Business Wire28d
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders -- -- Gilead ...